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httpcense.Abstract Background: Heart failure (HF) is frequently complicated by elevated pulmonary vascu-
lar resistance associated as a result of dysregulation of nitric oxide-mediated vascular smooth mus-
cle tone. The resulting pulmonary hypertension directly affects right ventricular function and may
affect exercise capacity, morbidity, and mortality. Sildenaﬁl, a type 5 phosphodiesterase inhibitor,
lowers pulmonary vascular resistance in pulmonary hypertension by increasing intracellular levels
of the nitric oxide. The aim of the study was to evaluate the improvement of exercise performance,
ventilatory efﬁciency, and pulmonary hypertension after 8 weeks of regular sildenaﬁl use in outpa-
tients with CHF.
Methods and results: Fourty patients with controlled heart failure on standard antifailure treat-
ment were enrolled in this study. Half of them received sildenaﬁl 50 mg twice daily for 8 weeks and
the other half was taken as a control group. Echo-Doppler, cardiopulmonary exercise testing, and
clinical follow-up were done. There was a statistically signiﬁcant drop of PAP in the sildenaﬁl group
from 58.4 ± 2 mmHg to 40.3 ± 0.5 mmHg and improvement in VO2 Peak, VE/VCO2 slope, T-1/2
Vo2 (min) and T-1/2 VCO2 (min) from 17.2 ± 2, 39.1 ± 6, 2.0 ± 0.5 and 2.0 ± 0.4 to 20 ± 2.5,
42.1 ± 5, 1.9 ± 0.7 and 1.8 ± 0.2 respectively (p< 0.05). Seven patients of the sildenaﬁl group
(35%) showed improvement of functional class from NYHA class II to class I. Concerning cardiac
events during follow up period, as regards active group, decompensated heart failure occurred in 1
patient (5%), ischemia occurred in 1 patient (5%), and arrhythmias occurred in 2 patients (10%),
while in the control group, decompensated heart failure occurred in 7 patients (35%), ischemia2465890.
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478 M.H. Ibrahim, M.A. Elmahdyoccurred in 4 patients (20%), and arrhythmias occurred in 5 patients (25%), no CVA occurred in
both groups.
Conclusions: The present study showed that in patients with systolic HF, type 5 phosphodiester-
ase inhibition with sildenaﬁl lowers the pulmonary artery pressure signiﬁcantly and improved ven-
tilatory efﬁciency monitored by VE/VCO2 slope, oxygen uptake kinetics and also improved exercise
performance.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction and aim of the work
Despite multiple pharmacologic and non-pharmacologic strate-
gies for the management of chronic heart failure (CHF), most
patients report some limitation in their exercise capacity during
the natural course of the syndrome [1]. In fact, exercise intoler-
ance dominates the clinical presentation of moderate to severe
CHF and is a major determinant of overall prognosis [2].
Multiple mechanisms seem to interfere with exercise perfor-
mance in CHF, including central (cardiopulmonary) and
peripheral (vascular) components. In particular, pulmonary
hypertension is an important predictor of functional disability
in CHF [3].
Endothelial dysfunction is also a well-recognized feature of
CHF that has been implicated in both its clinical presentation
and prognosis [4]. Endothelial dysfunction in CHF is associ-
ated with reduced vascular nitric oxide (NO) release [3].
Inhibition of 50-phosphodiesterase by sildenaﬁl has proven
to be beneﬁcial in different scenarios where endothelial func-
tion and vascular tone can be positively inﬂuenced [5].
These beneﬁcial effects are mediated in part by increases of
NO availability to the vascular bed [6]. Moreover, a growing
body of evidence shows that sildenaﬁl consistently improves
pulmonary hypertension caused by conditions other than
CHF [7].
Later, Lewis and coworkers showed that sildenaﬁl im-
proved functional capacity and decreased pulmonary pressure
in patients with CHF [8].
The aim of the study was to evaluate the effect of a 50 mg
dose twice daily of sildenaﬁl on exercise performance, ventila-
tory efﬁciency, oxygen uptake kinetics, pulmonary hyperten-
sion after 8 weeks in outpatients with CHF.
Patients and methods
This study was conducted at Benha University Hospital and it
included 40 patients with chronic heart failure receiving stan-
dard medical therapy for CHF.
These patients were divided randomly into two equal
groups:
Group (I): the control group that received the standard
anti-failure therapy.
Group (II): the active group that received 50 mg sildenaﬁl
twice daily in addition to standard medical therapy.
Inclusion criteria:
(1) Patients with chronic left ventricular systolic dysfunc-
tion (left ventricular ejection fraction more than 30%
and less than 50%) on standard medical therapy for
CHF [9].(2) All included patients were more than 20 years of age and
clinically stable for at least 2 months before inclusion in
the study.
(3) Good functional capacity determined on the basis of the
patients ability to perform certain daily tasks (average
4–10 METS).
Exclusion criteria:
(1) History of intolerance to sildenaﬁl.
(2) Concomitant use of nitrates.
(3) Systolic arterial pressure less than 90 mmHg.
All patients included in the study were subjected to careful
history analysis, full clinical examination, baseline Echo-
Doppler study particularly focusing in assessment of the LV
function and pulmonary artery pressure, and baseline cardio-
pulmonary exercise testing.
These patients were followed up over a period of 8 weeks
looking particularly for the functional class, cardiac decom-
pensation, ischemic attacks, arrhythmias and CVA. Follow
up of Echo-Doppler, and cardiopulmonary exercise testing
was done at the end of the 8 weeks.Echo-Doppler assessment of PASP
Echo-Doppler study was performed using a commercially
available ultrasound machine equipped with a 2.5-MHz trans-
ducer (Vivid7), using harmonic imaging. Estimation of PASP
was performed by summing the pressure gradient between
the right atrium and right ventricle (in the presence of tricuspid
regurgitation) and the estimated right atrial pressure. Right at-
rial pressure was calculated according to inferior vena cava
diameter and collapsibility index [10].
Left ventricular end-systolic and end-diastolic dimensions
were obtained from the parasternal short axis or long axis
view, and left ventricular fractional shortening and ejection
fraction were calculated [11].Cardiopulmonary exercise testing
Maximal functional capacity was obtained by an ergospiro-
metric examination performed on a treadmill (Jaeger ER
900) through an incremental exercise test and expired gas anal-
ysis. [8] A ramp-staged protocol was used, starting at 2.4 km/h
with an inclination of 1% to 2%, followed by progressive
speed increments of 0.1 to 0.12 km/h every 20 s, and 0.5% to
1.0% increases in slope every 60 s, until volitional fatigue
was reached.
Improvement of exercise performance and ventilatory efﬁciency in patients 479Gas exchange and ventilatory variables were analyzed using
a calibrated computer-based exercise system (Cortex
Biophysik Metalyzer 3B Stationary CPX system, Ml3B2.1,
Leipzig, Germany).
Data were obtained breath by breath and expressed as 15-s
averages. VO2 peak was deﬁned as the highest value of oxygen
consumption in the ﬁnal 15-s period of exercise.
Ventilatory efﬁciency was estimated using the relationship
between minute ventilation (VE) and carbon dioxide output
(VCO2), by linear regression model using all data points
obtained during the cardiopulmonary exercise test.
The following parameters were obtained to assess func-
tional capacity of the patients:
(1) VE peak (L/min); minute ventilation = tidal volume X
respiratory rate.
(2) VO2 peak (Ml/kg/min); O2 consumption.
(3) VCO2 peak (L/min); maximum CO2 production.
(4) R peak; VO2 peak/VCO2 peak.
(5) VE/VCO2 slope; minute ventilation/CO2 production.
(6) T-1/2 VE (min); Half time of minute ventilation.
(7) T-1/2 VO2 (min); Half time of O2 consumption.
(8) T-1/2 VCO2 (min); Half time of CO2 production.
Results
Among the thirty patients with HF participated in the present
study, baseline patient characteristics, etiological factors of
heart failure and medications were nearly matched among
both groups with no signiﬁcant difference between them. All
patients had undergone optimization of their HF pharmaco-
therapy before enrollment in the study. All patients in this
study had NYHA functional class I–II at the entry of the
study. None of the patients had evidence of a signiﬁcant under-
lying pulmonary disease.
Echo-Doppler data obtained at baseline and after 8 weeks
showed no signiﬁcant difference between both groups regard-
ing EF of the LV all through the study period however the
PASP that was comparably elevated in both groups at the start
of the study showed a signiﬁcant drop in the sildenaﬁl group
after 8 weeks with no change in the placebo group.
Regarding Cardiopulmonary Exercise Test Parameters, a
signiﬁcant improvement in VO2 Peak, VE/VCO2 slope, T-1/2
Vo2 (min) and T-1/2 VCO2 (min) occurred, from 17.2 ± 2,
39.1 ± 6, 2.0 ± 0.5 and 2.0 ± 0.4 to 20 ± 2.5, 42.1 ± 5,
1.9 ± 0.7 and 1.8 ± 0.2 respectively (p< 0.05), while in the
control group, there was no signiﬁcant improvement in all
parameters.
Clinical follow up of the patients showed that decompen-
sated heart failure occurred in 1 patient (5%) of the sildenaﬁl
group, ischemia occurred in another patient (5%) and arrhyth-
mias occurred in 2 patients (10%), while in the control group,
decompensated heart failure occurred in 7 patients (35%),
ischemia occurred in 4 patients (20%), arrhythmias occurred
in 5 patients (25%) which is statistically signiﬁcant, no CVA
occurred in both groups during follow up period. Concerning
mortality during follow up period, there was no mortality
cases in the both groups.Discussion
Because sildenaﬁl is a potent pulmonary vasodilator, even
more than inhaled nitric oxide however, it is not pulmonary
vascular speciﬁc. [12] We conducted our study to investigate
whether a 50 mg dose twice daily of sildenaﬁl could improve
exercise performance, ventilatory efﬁciency, oxygen uptake
kinetics, pulmonary hypertension after 8 weeks in outpatients
with CHF.
The protocol of sildenaﬁl use was variable across the differ-
ent studies, in the current study, the patients received sildenaﬁl
50 mg twice daily for 8 weeks, while Chockalingam, et al., gave
sildenaﬁl at 50 mg twice daily for 4 weeks, and increased to
100 mg bid for 4 more weeks in a step up protocol. [13] Also
Sastry [14] gave sildenaﬁl 25 to 100 mg tid on the basis of body
weight for 6 weeks and Galie` et al. [15] gave sildenaﬁl 20 mg to
10 patients, 40 mg to 15 patients, 80 mg to 20 patients orally
three times daily for 12 weeks.
According to our regimen some patients reported side ef-
fects from sildenaﬁl in the form of ﬂushing in 4 patients
(20%), headache in 2 patients (10%) and diarrhea in 1 patient
(5%), however these side effects did not interrupt treatment.
The ages of the patients in the current study ranged from 36
to 72 years, with mean age 54 ± 18 years, the majority of them
(65%) were below 60 years of age and male (Table 1). While
Humbert et al. [16] investigated 10 patients (2 males & 8 fe-
males), mean age 34.5 ± 3.3 years also Chockalingam et al.
[13] investigated 15 patients (10 males & 5 females), mean
age 44.5 ± 5.3 years.
This study was evaluating the effect of sildenaﬁl on patients
with mild heart failure as all patients were in functional class
(I–II) at the entry of the study after optimized and intensiﬁed
treatment. However, Chockalingam et al. [13] investigated the
patients who were severely symptomatic dyspnea NYHA class
(III–IV) while Humbert et al. [16] investigated patients who
presented with dyspnea NYHA class (II) (50%) and NYHA
class III (50%).
Regarding the clinical follow up, seven patients (35%) of
the sildenaﬁl group who presented with dyspnea grade (II),
showed subjective improvement to dyspnea grade (I), while
in the control group, there was no signiﬁcant improvement
in the grade of dyspnea in the studied population, This was
in concordance with Humbert et al. [16] who reported that
four patients (40%) who were presented with dyspnea NYHA
class III showed improvement in the grade of dyspnea (3 im-
proved to class II and one improved to class I) on regular sil-
denaﬁl intake of 50 mg t.d.s. for 3 months.
On the other hand, concerning adverse cardiac events dur-
ing follow up period, there was statistically signiﬁcant differ-
ence between the two groups. Decompensated heart failure
occurred in 1 patient (5%) of the sildenaﬁl group vs 7 patients
(35%) of the control group (P value <0.05), new onset ische-
mia occurred in 1 patient (5%) of the sildenaﬁl group vs 4 pa-
tients (20%) of the control group (P value <0.05) and
documented arrythmias occurred in 2 patients (10%) of the ac-
tive group vs 4 patients (26%) of the control group (P value
<0.05), no CVS occurred in both groups (Fig. 1). While Hum-
bert et al. [16] reported decompensated heart failure in 2 pa-
tients (20%), arrhythmia in 3 patients (30%), with regular
sildenaﬁl intake 50 mg t.d.s. for 3 months. However, Galie`
Table 1 Baseline patient characteristics.
Sildenaﬁl Control P value
No % No %
Age >60 7 35 8 40 (0.05)
<60 13 65 12 60
Sex Male 13 65 13 65 (0.05)
Female 7 35 7 35
HTN Yes 7 35 10 50 (0.05)
DM Yes 12 60 10 50 (0.05)
Smoking Yes 12 60 10 50 (0.05)
Dyslipidemia Yes 12 60 15 75 (0.05)
Family history Yes 10 50 13 65 (0.05)
Obesity 9 45 13 65 (0.05)
etiology of heart failure
Ischemic 5 25 7 35 >0.05
Valvular 3 15 4 20 >0.05
Others 12 60 9 45 >0.05
Medications
Diuretics 20 100 20 100 >0.05
Beta-blockers 19 95 17 85 >0.05
ACE-inhibitor 20 100 20 100 >0.05











Figure 1 Cardiac events in the studied group.
480 M.H. Ibrahim, M.A. Elmahdyet al. [15] reported that no statistically signiﬁcant clinical wors-
ening was observed with sildenaﬁl as compared with placebo.
Regarding mortality during follow up period, there were no
mortality cases in the two groups. Kothari and Duggal [17]
reported that 2 of 14 patients died after 6 and 7 months of
daily dose of 150 mg sildenaﬁl.
In the current study, cardiac events at follow up were re-
ported more in patients aged ore than 60 years (31.1% vs.
20%, p< 0.05). This is consistent with Chockalingam et al.
[13] that reported signiﬁcant complication at 2 month follow
up among patients aged more than 60 years. On the other hand
Sastry [14] found no signiﬁcant complication difference inTable 2 Echo-Doppler data.
Sildenaﬁl P va
Before After
EF 40 ± 1.0 38 ± 2.0 >0.0
PASP 58 ± 2 40 ± 0.5 >0.0between patients aged less than 60 years and older at 6 week
follow up.
Regarding Echo-Doppler follow up, in the current study,
the mean PASP before giving the sildenaﬁl was
58.4 ± 2 mmHg which was signiﬁcantly reduced to
40.3 ± 0.5 mmHg after 8 weeks of regular sildenaﬁl intake,
so there was a reduction in mean PASP 18 ± 1.5 mmHg (aver-
age 30%) (P value <0.05), while in the control group, there
was no signiﬁcant reduction in mean PASP (P value >0.05)
(Table 2). These results were concordant with results of Guazzi
et al. [18] who reported a reduction in mean PASP values (up
to 20%), however, there was no change in cardiac output. This
was supported by the results of Chockalingam et al. [13] who
reported a decrease in mean pulmonary artery pressure (up
to 25%) with sildenaﬁl 50 mg bid at 4 weeks also Jackson
et al. [19] who reported that sildenaﬁl 100 mg PO reduced basal
PASP by 27% in men with ischemic heart disease. Galie` et al.
[15] reported that all sildenaﬁl doses (20, 40, 80 mg) orally
three times daily for 12 weeks reduced the mean pulmonary ar-
tery pressure P= 0.04, P= 0.01 and P< 0.001, to
P= 0.003, P< 0.001 and P< 0.001, respectively.
As regards the study of cardiopulmonary function test, pa-
tients were assessed 8 weeks after sildenaﬁl intake and signiﬁ-
cant improvement in VO2 Peak, VE/VCO2 slope, T-1/2 Vo2
and T-1/2 VCO2 (min) from 17.2 ± 2, 39.1 ± 6, 2.0 ± 0.5
and 2.0 ± 0.4 to 20 ± 2.5, 42.1 ± 5, 1.9 ± 0.7 and 1.8 ± 0.2
respectively occurred (P value <0.05) (Table 3). This was in
concordance with Wong et al. [20] who reported signiﬁcantlue Control P value
Before After
5 39 ± 1.0 38 ± 0.5 >0.05
5 57 ± 1 55 ± 1 >0.05
Table 3 Cardiopulmonary exercise test parameters.
Control Sildenaﬁl
Before After Before After
Peak exercise
VE peak, L/min1 49 ± 11 50 ± 10 50 ± 11 55 ± 12
VO2 peak, mL/kg
1/min 1 16.4 ± 3 17 ± 2 17.2 ± 2 20 ± 2.5
VCO2 peak, L/min
1 20 ± 7 20 ± 6 18 ± 3 19 ± 3
R peak 1.04 ± 0.1 1.o5 ± 0.1 1.03 ± 0.1 1 ± 0.1
Ventilatory eﬃciency
VE/VCO2 slope 44.7 ± 6 44.9 ± 6 39.1 ± 6 42.1 ± 5
Recovery gas exchange
T-1/2 VO2 (min) 2.6 ± 0.7 2.66 ± 0.8 2.66 ± 0.8 1.9 ± 0.7
T-1/2 VCO2 (min) 2.5 ± 1 2.6 ± 0.9 2.6 ± 0.9 1.8 ± 0.2
Improvement of exercise performance and ventilatory efﬁciency in patients 481improvement in peak VO2, Peak O2 pulse, VE/VCO2 and PET
Co2 from 0.84 ± 0.1 L/min, 6.1 ± 0.7 ml. beat
1, 49 ± 2 and
26 ± 1.5 mmHg to 0.91 ± 0.1 L/min, 6.8 ± 0.8 m. beat1,
43 ± 2 and 30 ± 1.9, respectively after adding sildenaﬁl
50 mg twice daily for 4 months.
Conclusion
According to our study, sildenaﬁl is beneﬁcial in alleviating the
morbidity of mild heart failure subjectively as assessed by func-
tional class and objectively as assessed by cardiopulmonary
exercise testing.
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